The drug has been specifically authorised in combination with etoposide and platinum chemotherapy to treat adult patients with extensive-stage small cell lung cancer (SCLC ... in a 25% reduction in ...

The antibody-drug conjugate (ADC) is currently under review by the FDA as a treatment for advanced or metastatic non-squamous non-small cell lung cancer ... progression or death by 43% versus ...

As of March 31, 2025, Merus had $638 million cash, cash equivalents and marketable securities. Based on the Company's current operating plan, the existing cash, cash equivalents and marketable ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.

French drugmaker Sanofi has halted the development of its antibody-drug conjugate (ADC) tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung cancer (NSCLC).

There is a commercial access agreement for osimertinib. NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS organisations can contact ...

Stage 3 lung cancer is considered locally advanced with spread in the region near the site. Survival rates for stage 3 non-small cell lung cancer (NSCLC) range from as high as 36% to as low as 13%, ...

Their findings, published in Nature Cancer, may help improve future ways to deliver this cellular immunotherapy for metastatic non-small cell lung cancer. TIL therapy is a live cell treatment where a ...

aDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH, USA bDepartment of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, ...